FMR1 and fragile X syndrome: These platforms have enabled proof-of-concept disease modification in neuronal systems, encompassing the reactivation of FMR1 in neurons derived from patients with FXS [54], the enhancement of neuroprotective BDNF signaling [61], and the suppression of pathogenic α-synuclein expression in PD models [59, 62].